The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Have emailed my MP and health reporter for a national newspaper.
Re 'Divoc have added a ‘Book a Test’ page to their website now. Still moving forward.'
They are advertising for a data entry operator as well. Posted on 6/11/20.
https://www.workindia.in/jobs/data_entry_operator-chittaranjan_park-delhi-1104919/
Another article here:
https://www.*************.net/cytiva-strengthens-support-to-diagnostics-industry/
'Cytiva has already been working with diagnostic developers during the COVID-19 pandemic. In total, over 50 million people have been PCR tested using components or services from Cytiva.'
https://www.biocompare.com/Life-Science-News/562900-SARS-CoV-2-COVID-19-Research-News-Latest-Updates/
Afternoon, likewise I took a small position here this morning. Did hold some earlier in the year but sold so back again for a re-run!
Recent news on DIVOC labs:
'It also offers TRUNAAT, RT PCR and Antigen COVID Testing pending ICMR notifications and approvals.'
https://www.expresshealthcare.in/archive/latest-updates/divoc-health-set-to-launch-20-new-telemedicine-laboratories-in-india-by-2021/425401/
http://bwdisrupt.businessworld.in/article/DIVOC-Health-Set-To-Launch-20-New-Telemedicine-Laboratories-In-India-By-2021-/21-10-2020-333888/
'genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company's Point-of-Care ("POC") solution for COVID-19 testing and is now generating very promising analytical data aligned to market requirements.
The Genedrive® SARS-CoV-2 POC Kit is being designed to detect SARS-CoV-2, the virus causing COVID-19, amplified directly from a saliva sample without the need to extract viral RNA. This expands the potential use areas of the product and importantly, allows for rapid testing to be performed while a patient is present. When running on the Genedrive® POC device the chemistry is detecting a positive SARS-CoV-2 sample in approximately 15 minutes, with fully negative samples taking just over 20 minutes to resolve. The limit of detection is in line with the UK's MHRA Target Product Profile sensitivity requirements.
The Genedrive SARS-CoV-2 POC Kit follows a similar workflow that has already been validated in the Company's Genedrive® HCV-ID Kit which received WHO pre-qualification earlier this year.
The Company is targeting the end of the calendar year for completion of preliminary product evaluations, with full release of the final CE Marked system in Q1 2021 allowing for thorough clinical testing requirements. Additionally, the Company is working to progress to a version 2 of the product, which would accept a similar freeze-dried PCR bead format previously developed for the high throughput Genedrive® 96 SARS-CoV-2 Kit. This will allow for lower production costs and highly scalable manufacturing capacity.'
https://www.londonstockexchange.com/news-article/GDR/holding-s-in-company/14724653
@Tolster
https://mergr.com/danaher-acquisitions
"Danaher has acquired 42 companies, including 8 in the last 5 years. A total of 10 acquisitions came from private equity firms. It has also divested 9 assets. Danaher’s largest acquisition to date was in 2019, when it acquired GE Biopharma for $21.4B. It’s largest disclosed sale occurred in 2015, when it sold Danaher Corp - Communications Business to NetScout Systems for $2.3B. Danaher has acquired in 12 different US states, and 12 countries. The Company’s most targeted sectors include test/measurement equipment (24%) and medical products (21%)."